Sun Sentinel Broward Edition

US advisers endorse 1-dose COVID-19 vaccine from J&J

- By Lauran Neergaard and Matthew Perrone

WASHINGTON — U.S. health advisers endorsed a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic.

The Food and Drug Administra­tion is expected to quickly follow the recommenda­tion and make J&J’s shot the third vaccine authorized for emergency use in the U.S. Vaccinatio­ns are picking up speed, but new supplies are urgently needed to stay ahead of a mutating virus that has killed more than 510,000 Americans.

After daylong discussion­s, the FDA panelists voted unanimousl­y that the benefits of the vaccine outweighed the risks for adults. If the FDA agrees, shipments of a few million doses could begin as early as Monday.

The company has said it can deliver 20 million doses by the end of March and a total of 100 million by the end of June.

J&J’s vaccine protects against the worst effects of COVID-19 after one shot, and it can be stored up to three months at refrigerat­or temperatur­es, making it easier to handle than the previous vaccines, which must be frozen.

The two-dose Pfizer and Moderna shots were found to be about 95% effective against symptomati­c COVID19. The numbers from J&J’s study are not that high, but it’s not an apples-to-apples comparison. One dose of the J&J vaccine was 85% protective against the most severe COVID-19. After adding in moderate cases, the total effectiven­ess dropped to about 66%.

Some experts fear that lower number could feed perception­s that J&J’s shot is a “second-tier vaccine.” But the difference in protection reflects when and where J&J conducted its studies.

J&J’s vaccine was tested in the U.S., Latin America and South Africa when more contagious mutated versions of the virus were spreading. That wasn’t the case last fall, when Pfizer and Moderna were wrapping up testing, and it’s not clear if their numbers would hold against the most worrisome of those variants.

The FDA reported this week that, like its predecesso­rs, the J&J shot offers strong protection against the worst outcomes, hospitaliz­ation and death.

 ??  ?? Vials of Johnson & Johnson’s one-dose COVID-19 vaccine. JOHNSON & JOHNSON 2020
Vials of Johnson & Johnson’s one-dose COVID-19 vaccine. JOHNSON & JOHNSON 2020

Newspapers in English

Newspapers from United States